The study also found that high FTO expression was correlated with shorter median progression-free survival (HR = 1.51, 95% CI: 1.42–2.24, P < .001) and recurrence-free survival (RFS) (HR = 1.47, 95% CI: 1.07–2.02, P < .001).[34,35] Therefore, FTO may serve as a novel biomarker for predicting the prognosis of gastric cancer and as a potential target for therapeutic interventions. This evidence concerns the gene FTO and gastric cancer.